Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Sees Large Decline in Short Interest

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 11,800 shares, a decrease of 41.6% from the September 30th total of 20,200 shares. Based on an average daily trading volume, of 36,900 shares, the short-interest ratio is presently 0.3 days.

Scinai Immunotherapeutics Stock Performance

Shares of Scinai Immunotherapeutics stock opened at $3.45 on Friday. The firm has a market cap of $1.60 million, a PE ratio of -0.01 and a beta of 2.47. The business’s 50 day simple moving average is $3.72 and its 200 day simple moving average is $3.90. Scinai Immunotherapeutics has a 52-week low of $2.23 and a 52-week high of $8.92.

Scinai Immunotherapeutics (NASDAQ:SCNI) last posted its earnings results on Thursday, August 15th. The company reported ($3.57) EPS for the quarter. The company had revenue of $0.28 million for the quarter.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.